| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6177345 | European Urology | 2016 | 9 Pages |
Abstract
Incorporation of two prostate cancer (PCa)-specific biomarkers (TMPRSS2:ERG and PCA3) measured in the urine improved on serum prostate-specific antigen (or a multivariate risk calculator) for predicting the presence of PCa and high-grade PCa on biopsy. A combined test, Mi-Prostate Score, uses models validated in this study and is clinically available to provide individualized risk estimates.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Scott A. Tomlins, John R. Day, Robert J. Lonigro, Daniel H. Hovelson, Javed Siddiqui, L. Priya Kunju, Rodney L. Dunn, Sarah Meyer, Petrea Hodge, Jack Groskopf, John T. Wei, Arul M. Chinnaiyan,